Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $64.0 million.

  • Amylyx Pharmaceuticals' Change in Acquisitions & Divestments fell 1466.67% to $64.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.0 million, marking a year-over-year decrease of 4120.68%. This contributed to the annual value of $344.0 million for FY2024, which is 1271.69% down from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Change in Acquisitions & Divestments is $64.0 million, which was down 1466.67% from $62.0 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Change in Acquisitions & Divestments ranged from a high of $147.9 million in Q4 2023 and a low of $24.9 million during Q1 2022
  • Over the past 4 years, Amylyx Pharmaceuticals' median Change in Acquisitions & Divestments value was $65.0 million (recorded in 2024), while the average stood at $73.6 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 33505.88% in 2023 and then crashed by 5605.73% in 2024.
  • Quarter analysis of 4 years shows Amylyx Pharmaceuticals' Change in Acquisitions & Divestments stood at $34.0 million in 2022, then skyrocketed by 335.06% to $147.9 million in 2023, then crashed by 56.06% to $65.0 million in 2024, then decreased by 1.54% to $64.0 million in 2025.
  • Its last three reported values are $64.0 million in Q3 2025, $62.0 million for Q2 2025, and $60.0 million during Q1 2025.